Market Place
Sourcing Support
U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
19 Mar 2024 //
PFRESS RELEASE
ViiV Healthcare Announces Data at CROI Indicating Efficacy of Cabenuva
06 Mar 2024 //
BUSINESSWIRE
GSK`s injectable HIV drug shows promise over daily pills
22 Feb 2024 //
PRESS RELEASE
ViiV Healthcare receives approval from China’s NMPA for Vocabria
27 Oct 2023 //
PRESS RELEASE
Janssen`s Rekambys (Rilpivirine) Receives Approval in Europe
08 Jun 2023 //
EMA
Hagens Berman Sobol , Hilliard Announce a Class Action Antiretroviral Drugs
28 Dec 2022 //
PR NEWSWIRE
FDA approves Gilead`s long-acting HIV injectable Sunlenca
23 Dec 2022 //
FIERCEPHARMA
ViiV Presents Showing Vocabria & Rekambys Can Be Implemented in EU Healthcare
24 Oct 2022 //
BUSINESSWIRE
FDA Approves CABENUVA; Expands Indication of Injectable HIV Regimen
29 Mar 2022 //
PRESS RELEASE
ViiV wins another label update for long-acting HIV injectable Cabenuva
25 Mar 2022 //
ENDPTS
ViiV Healthcare announces EC Decision for Vocabria, Rekambys injections for HIV
28 Oct 2021 //
BUSINESSWIRE
Long-Acting Cabotegravir, Rilpivirine Inj. Effective Maintenance Therapy for HIV
20 Jul 2021 //
PRESS RELEASE
FDA approves first extended-release injectable, complete regimen for HIV
22 Jan 2021 //
EUROPEANPHARMACEUTICALREVIEW
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir)
21 Jan 2021 //
PRNEWSWIRE
FDA approves first extended-release injectable, complete regimen for HIV
21 Jan 2021 //
EUROPEANPHARMACEUTICALREVIEW
US green light for long-acting HIV regimen Cabenuva
21 Jan 2021 //
PHARMATIMES
EU nod for first long-acting HIV injectable treatment
21 Dec 2020 //
PHARMATIMES
GSK says it is within weeks of resubmitting HIV injection Cabenuva
02 Jul 2020 //
REUTERS
Minakem announces New Patent for a new process of preparation of Rilpivirine
20 May 2020 //
PRESS RELEASE
GSK`s ViiV nabs first approval for HIV game-changer Cabenuva
21 Mar 2020 //
FIERCE PHARMA
Positive Recommendation by NICE for first anti-CGRP migraine therap
12 Mar 2020 //
BUSINESSWIRE
ViiV Healthcare presents positive 48-week data from phase III study
09 Mar 2020 //
BUSINESS WIRE
Eight weeks between each HIV treatment? GSK notches PhIII win as it chases OK
23 Aug 2019 //
ENDPTS
Janssen reports positive Ph3 results of long-acting injectable HIV treatment
23 Aug 2019 //
BIOSPECTRUMASIA
ViiV’s long-acting HIV regimen passes late-stage trial
22 Aug 2019 //
CLINICALTRIAL SARENA
ViiV submits regulatory application to EMA for investigational HIV combo
29 Jul 2019 //
PHARMA TIMES
Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
21 Jun 2019 //
FIERCE PHARMA
ViiV submits NDA for first long-acting, injectable HIV combo
02 May 2019 //
PHARMA TIMES
Positive results for monthly HIV drug
11 Mar 2019 //
PHARMA TIMES
GlaxoSmithKline`s ViiV touts more two-drug HIV success
09 Mar 2019 //
FIERCE PHARMA
ViiV Healthcare`s HIV med Juluca OK`d in Japan
28 Nov 2018 //
SEEKING ALPHA
GlaxoSmithKline`s Shingrix zooms toward blockbuster status despite tight supply
31 Oct 2018 //
FIERCE PHARMA
Long-lasting HIV injection is a step closer after second GSK study
31 Oct 2018 //
REUTERS
Encouraging data for ViiV’s long-acting, two-drug HIV therapy
30 Oct 2018 //
PHARMA TIMES
Four new medicines available via NHS Scotland
12 Sep 2018 //
PHARMA TIMES
What`s in the Cards for Glaxo This Earnings Season?
24 Jul 2018 //
NASDAQ
Six medicines recommended for approval, including one orphan
24 Mar 2018 //
EMA
EMA’s CHMP Rejects Two Drugs Approved by US FDA in 2017
24 Mar 2018 //
RAPS
Fresh off its Juluca approval, GSK beefs up trials of long-acting HIV duo
28 Nov 2017 //
FIERCE PHARMA
Glaxo turns up the heat on Gilead with landmark 2-drug HIV win
22 Nov 2017 //
FIERCE PHARMA
ViiV’s long-acting two-drug HIV regimen hits targets
25 Jul 2017 //
PHARMA TIMES
GSK says ViiV Healthcare submits 2-drug HIV regimen application to EMA,U.S. FDA
02 Jun 2017 //
REUTERS
ViiV Healthcare Files Regulatory Submissions for First Two-Drug
01 Jun 2017 //
DDDMAG
ViiV study shows efficacy of two-drug HIV regimen
15 Feb 2017 //
PHARMATIMES
GSK details PhIII success, preps global rollout for HIV combo
14 Feb 2017 //
ENDPOINTS
ViiV Kicks Off PhIII Trials of HIV Regimen
22 Nov 2016 //
PHARMATIMES
EU nod for Gilead’s single-pill HIV therapy
25 Jun 2016 //
PHARMATIMES
J&J and ViiV line up Phase III trials for a long-acting HIV treatment
25 Feb 2016 //
FIERCE BIOTECH
ViiV Healthcare Announces PhII Study Results for First Two Drug
23 Feb 2016 //
PR NEWSWIRE
Blockbuster new launches coming from Intercept, Gilead and Merck: Reuters
04 Feb 2016 //
FIERCE PHARMA
ViiV to Progress Collaboration with Janssen to Develop First Long-acting
08 Jan 2016 //
PR NEWS WIRE
ViiV Announces Positive Results from a Study for HIV Maintenance Therapy
04 Nov 2015 //
PR NEWS WIRE
ViiV Healthcare Attacking, but Gilead Prepares to Strike Back
03 Nov 2015 //
MOTLEY FOOL
